REDWOOD CITY, Calif., May 18, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. announced today that the results from its Phase 2 clinical studies related to two product candidates, ARX-01 Sufentanil NanoTab(R) PCA System, which is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia and ARX-03 to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office, will be featured in poster presentations at the upcoming American Pain Society Annual Meeting to be held in Austin, TX, on May 18th-21st, 2011. Commenting on the poster presentations, Pamela Palmer, MD, PhD, AcelRx co-founder and Chief Medical Officer said, "We are delighted that these data are being presented at this prestigious meeting by investigators involved in the studies. In particular, the combined data from ARX-01 Phase 2 studies highlight advantages of our post-operative pain management approach over existing methods that we hope to confirm in our Phase 3 studies."
Lead investigator, Harold Minkowitz, MD of the Memorial Hermann Memorial City Medical Center in Houston, TX will present analyses of the combined results from two randomized, placebo-controlled Phase 2 studies and one Phase 2 open-label system functionality study evaluating the safety and efficacy of the ARX-01 sublingual Sufentanil NanoTab(R) PCA System. ARX-01 is a non-invasive, sublingual alternative to intravenous patient-controlled analgesia (IV PCA). The results from the 212 patients included in these three studies indicate that ARX-01 was effective in treating both major orthopedic and major abdominal post-operative pain with minimal adverse effects.
Also presented will be results from a randomized, placebo-controlled Phase 2 study to evaluate the safety and effectiveness of ARX-03, a novel sublingual combination of sufentanil and triazolam that offers mild sedation, anxiolysis and analges